What is mazdutide? Structure, research and status

Mazdutide is a dual GLP-1 and glucagon receptor agonist that Innovent Biologics licensed from Eli Lilly and brought to approval in China in 2025.

Complete guide10 min read

Key takeaway

Mazdutide is a 33-amino-acid peptide with an attached fatty acid chain. Four Phase 3 trials in Chinese adults have been published. In GLORY-1, mean body weight fell 11.00% and 14.01% in the two mazdutide groups at week 48, versus a 0.30% gain on placebo. The most common reported side effects were gastrointestinal.

At a glance

Article typeComplete guide
Regulatory statusIn clinical trials“Mazdutide is not approved by the FDA and is still in clinical trials in the United States.” (this article)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited9 in this article · 9 across 1 article on Mazdutide
Related productsIncretin analogs

Mazdutide is a synthetic peptide modeled on oxyntomodulin, a gut hormone that activates both the GLP-1 and glucagon receptors. China's drug regulator approved it for weight management in June 2025 and for type 2 diabetes in September 2025. FDA has not approved it.

Quick answer: Mazdutide is an approved medicine in China, under the brand name Xinermei, and an investigational one in the United States. Mazdutide is not approved by the FDA and is still in clinical trials in the United States. Approval in China does not make research material sold under the same name an approved medicine.

Vitrapep does not sell mazdutide; this page is a reference summary of published research and regulatory information.

What is mazdutide and how is it built?

Mazdutide is a long-acting synthetic analog of mammalian oxyntomodulin. A fatty acid side chain was added to extend its half-life [2]. Oxyntomodulin is a hormone the gut releases after meals. It activates both the GLP-1 receptor and the glucagon receptor [3].

Eli Lilly developed the molecule under the code LY3305677. Its first registered human study, in healthy participants, began in December 2016 (NCT02972645). Innovent Biologics holds an exclusive license from Lilly to develop and commercialize mazdutide in China, where it carries the code IBI362 [5].

PubChem's structure record shows a chain of 33 amino acids that ends in an amide [1]. Position 2 is aminoisobutyric acid, a non-standard amino acid. A lysine at position 20 carries a 20-carbon fatty diacid, joined through a short linker [1]. Semaglutide and tirzepatide also use fatty acid chains to last longer in the body (see what GLP-1 is).

Table 1

What is mazdutide and how is it built

PropertyMazdutide
ClassDual GLP-1 and glucagon receptor agonist; oxyntomodulin analog [2]
Structure33 amino acids with a C-terminal amide; aminoisobutyric acid at position 2; a 20-carbon fatty diacid on the lysine at position 20 [1]
Molecular formulaC207H317N45O65 (PubChem CID 167312357) [1]
Molecular weight4476 g/mol [1]
CAS number2259884-03-0 [1]
Development codesLY3305677 (Eli Lilly); IBI362 (Innovent Biologics) [1]
Terminal half-life6.3 to 16.8 days in a 12-week Phase 1b study [2]
First approvalChina, June 2025, for weight management; brand name Xinermei [4], [5]
Second approvalChina, September 2025, for glycemic control in type 2 diabetes [6]
US statusNot FDA-approved; no application listed in Drugs@FDA as of November 18, 2026

How does mazdutide work?

Mazdutide activates two receptors. The first is the GLP-1 receptor. Its activation raises glucose-dependent insulin release, lowers glucagon secretion, slows stomach emptying and acts on appetite pathways (see what GLP-1 is).

The second target is the glucagon receptor. Glucagon signals the liver to release glucose (see the glucagon complete guide). A 2014 review noted that glucagon receptor activation increases glucose production. Simultaneous GLP-1 receptor activation counteracts that effect [3]. The same review reported that oxyntomodulin reduces food intake and increases energy expenditure in humans [3].

Cell and animal findings. The Phase 1b report summarized early laboratory data on mazdutide. It bound human and mouse GLP-1 and glucagon receptors in cell assays. It lowered body weight in mice lacking either receptor. It also raised energy expenditure compared with vehicle, which semaglutide did not [2]. These mouse results were first presented as a conference abstract, not a full paper.

Tirzepatide activates the GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activity to those two (see the retatrutide complete guide). Published descriptions of mazdutide name only the GLP-1 and glucagon receptors as its targets [2], [4].

What is mazdutide approved for, and what is being studied?

China's National Medical Products Administration (NMPA) approved mazdutide in June 2025. The use is long-term weight management, with diet and physical activity, in adults with a body-mass index (BMI) of at least 28. Adults with a BMI of at least 24 and one or more weight-related conditions are also covered [4]. Innovent said the approval rested mainly on GLORY-1 [5].

These cutoffs follow Chinese definitions. Innovent's release defines overweight as a BMI of 24 to under 28 and obesity as 28 or higher [5]. On September 19, 2025, Innovent announced a second NMPA approval, for glycemic control in adults with type 2 diabetes [6].

FDA has not approved mazdutide for any use, and openFDA lists no application for it. Vitrapep's guide on how to find a peptide clinical trial explains these registry statuses.

Table 2

What is mazdutide approved for, and what is being studied

Condition studiedRegistry recordSponsorPhaseStatus on November 18, 2026
Obstructive sleep apnea with obesity (GLORY-OSA)NCT06931028Innovent3Recruiting
Fatty liver disease with overweight, versus semaglutideNCT06884293Innovent3Active, not recruiting
Adolescents with obesity or overweight (GLORY-YOUNG)NCT07255209Innovent3Recruiting
Type 2 diabetes with obesity, versus semaglutide (DREAMS-3)NCT06184568Innovent3Completed
Metabolic dysfunction-associated steatohepatitis (MASH)NCT06937749Innovent2Active, not recruiting
Heart failure with preserved or mildly reduced ejection fractionNCT06862908Innovent2Active, not recruiting
Alcohol use disorderNCT06817356Eli Lilly2Completed (US sites)

What did the key mazdutide trials show?

Four Phase 3 trials in Chinese adults have full results in peer-reviewed journals. Innovent employees were among the authors of all four, and Innovent funded GLORY-1 [7], [8], [9], [10].

GLORY-1 (NCT05607680) enrolled 610 adults with overweight or obesity. At week 32, 73.9% and 82.0% of the two mazdutide groups lost at least 5% of body weight, versus 10.5% on placebo [7]. At week 48, 35.7% and 49.5% lost at least 15%, versus 2.0% on placebo [7].

GLORY-2 (NCT06164873) tested a higher mazdutide dose than GLORY-1. It enrolled adults with a BMI of at least 30 at 27 hospitals. About 16.1% had type 2 diabetes [8]. At week 60, 84.3% on mazdutide had lost at least 5% of body weight, versus 33.1% on placebo [8].

DREAMS-1 (NCT05628311) enrolled 320 adults whose type 2 diabetes was not controlled by diet and exercise alone. Mean baseline HbA1c was 8.24%. A 24-week placebo-controlled period was followed by 24 weeks of extended mazdutide treatment [9].

DREAMS-2 (NCT05606913) compared mazdutide with dulaglutide in adults already taking oral diabetes medicines. Both mazdutide groups met the noninferiority and superiority tests for HbA1c [10]. Dulaglutide is FDA-approved as Trulicity (see the dulaglutide complete guide).

Table 3

What did the key mazdutide trials show

TrialPopulation and sizeDesign and lengthPrimary result
GLORY-1, NEJM 2025 [7]610 Chinese adults with overweight or obesityDouble-blind, placebo-controlled; 48 weeksWeight change at week 32: -10.09% and -12.55% with mazdutide vs +0.45% with placebo
GLORY-2, JAMA 2026 [8]461 treated Chinese adults with a BMI of 30 or moreDouble-blind, placebo-controlled, 2:1; 60 weeksWeight change at week 60: -16.65% vs -1.50%; difference -15.15 points
DREAMS-1, Nature 2026 [9]320 Chinese adults with type 2 diabetes on diet and exerciseDouble-blind, placebo-controlled; 24 weeks plus 24-week extensionHbA1c change at week 24: -1.57 and -2.15 points vs -0.14 with placebo
DREAMS-2, Nature 2026 [10]731 Chinese adults with type 2 diabetes on oral medicinesRandomized, versus dulaglutide; 28 weeksHbA1c difference vs dulaglutide: -0.24 and -0.30 points; weight difference -3.78 and -5.76 points

US Phase 2. Lilly ran a placebo-controlled trial at 24 US centers (NCT06124807). It enrolled 179 adults with obesity or overweight and without type 2 diabetes, for 48 weeks [11]. At 32 weeks, mean weight change ranged from -7.3% to -18.1% across three mazdutide groups, versus -0.9% on placebo [11].

What side effects have mazdutide trials reported?

Mazdutide has no US prescribing information, so no FDA label lists its adverse reactions or warnings. The safety data below come from published trials and registry results.

Table 4

What side effects have mazdutide trials reported

TrialMost common adverse events reportedStopped treatment because of adverse events
GLORY-1 [7]Gastrointestinal, mostly mild to moderate1.5% and 0.5% with mazdutide vs 1.0% with placebo
GLORY-2 [8]Vomiting 53.1% vs 1.3%; nausea 46.9% vs 3.2%; diarrhea 39.4% vs 6.5%2.9% with mazdutide vs 0% with placebo
DREAMS-1 [9]Diarrhea, decreased appetite and nauseaNot given in the abstract
DREAMS-2 [10]Diarrhea, nausea and vomiting; gastrointestinal events more common than with dulaglutideNot given in the abstract
US Phase 2 [11]Gastrointestinal, mostly mild to moderateHighest in the top-dose group, at 20%, mainly gastrointestinal

Heart rate. The Phase 1b report cited mouse evidence that oxyntomodulin raises heart rate through the glucagon receptor [2]. In a 20-week Phase 2 diabetes trial, mean heart rate rose 6.4 to 6.6 beats per minute with mazdutide [12]. It rose 7.5 with dulaglutide and 1.7 with placebo. Blood pressure fell in the mazdutide and dulaglutide groups [12].

Blood sugar. In the same trial, hypoglycemia occurred in 10% on mazdutide and 8% on placebo. No severe hypoglycemia was reported [12].

Early studies. The Phase 1b study in 36 adults reported no serious adverse events. Three participants on mazdutide had mild, asymptomatic heart findings on electrocardiogram. Two developed antibodies against the drug [2].

Serious events. In the US Phase 2 registry results, serious events occurred in 1 of 47 on placebo. Across the mazdutide groups, the counts were 1 of 32, 1 of 47 and 2 of 51. One acute cholecystitis case occurred in the top-dose group (NCT06124807 results).

What is the regulatory status of mazdutide?

United States. FDA has not approved mazdutide. FDA's page on unapproved GLP-1 drugs says it has warned companies that illegally sold unapproved drugs containing mazdutide [13]. The same warning covers semaglutide, tirzepatide, retatrutide and survodutide. FDA says these products were falsely labeled "for research purposes" or "not for human consumption" [13].

FDA adds that these products were sold to consumers for human use with dosing instructions. It calls them of unknown quality and possibly harmful [13]. Vitrapep summarizes the August 2026 FDA warning letters. A research-use-only label does not make a product legal or safe for people. See research peptides and human-use risks and why research peptides have no dose.

Clinical development in the United States. Lilly's Phase 2 obesity trial and its Phase 2 alcohol use disorder trial are both completed. A Lilly master protocol study that includes mazdutide is recruiting at US and Argentine sites (NCT06143956). ClinicalTrials.gov listed no Lilly-sponsored Phase 3 trial of mazdutide on November 18, 2026.

China. Mazdutide holds NMPA approvals for weight management and for type 2 diabetes [5], [6]. Innovent's license from Lilly covers China [5].

Sport. The 2026 WADA Prohibited List does not name mazdutide or GLP-1 receptor agonists [14]. Its S0 class covers substances with no current approval by any governmental regulatory health authority for human therapeutic use [14]. Mazdutide has held Chinese approval since June 2025 [4].

What is still unknown about mazdutide?

All published Phase 3 data come from Chinese adults. The largest published US trial is a 179-person Phase 2 study [11]. No cardiovascular outcomes trial of mazdutide appeared on ClinicalTrials.gov as of November 18, 2026.

The longest placebo-controlled Phase 3 period published so far is 60 weeks, in GLORY-2 [8]. Long-term effects of the heart rate rise are not known. Results from the fatty liver, heart failure, sleep apnea and adolescent trials are still pending.

Frequently asked questions

Is mazdutide a peptide?

Yes. PubChem's structure shows a chain of 33 amino acids with a 20-carbon fatty diacid attached through a linker.

Is mazdutide FDA-approved?

No. FDA has not approved mazdutide for any use. Lilly's US studies have reached Phase 2.

Where is mazdutide approved?

China approved mazdutide for weight management in June 2025 and for glycemic control in type 2 diabetes in September 2025. The brand name is Xinermei.

How is mazdutide different from tirzepatide and retatrutide?

Mazdutide activates the GLP-1 and glucagon receptors. Tirzepatide activates the GIP and GLP-1 receptors. Retatrutide activates all three.

What side effects did mazdutide trials report?

Gastrointestinal events were most common, mainly nausea, vomiting and diarrhea. Trials also reported heart rate increases. Some participants developed antibodies against the drug.

Is mazdutide banned in sport?

The 2026 WADA Prohibited List does not name mazdutide. The list's S0 class covers substances with no governmental approval for human therapeutic use.

What to know now

  • Mazdutide is a dual GLP-1 and glucagon receptor agonist built on the oxyntomodulin template.
  • China approved it in 2025 for weight management and type 2 diabetes; FDA has not approved it.
  • Four published Phase 3 trials in Chinese adults reported weight and HbA1c reductions versus placebo or dulaglutide.
  • FDA has warned companies that sold mazdutide labeled for research purposes to consumers.

What we’re watching

  • Results from the GLORY-OSA, fatty liver, MASH, heart failure and adolescent trials.
  • Published results from DREAMS-3, the completed comparison with semaglutide.
  • Whether Lilly moves mazdutide into Phase 3 trials outside China.

More for endocrine & metabolism

All 48 compounds for endocrine & metabolism

Sources: National Center for Biotechnology Information 2026; Ji 2021, EClinicalMedicine, 39; Pocai 2014, Molecular Metabolism, 3; Shirley 2025, Drugs, 85; Innovent Biologics 2025; Innovent Biologics 2025; Ji 2025, New England Journal of Medicine, 392; Gao 2026, JAMA, 336; Zhu 2026, Nature, 652; Guo 2026, Nature, 652; Hsia 2026, Lancet Diabetes & Endocrinology, 14; Zhang 2024, Diabetes Care, 47; U.S. Food and Drug Administration 2026; World Anti-Doping Agency 2025. All 14 citations

Back to the research library

References

  1. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 167312357, mazdutide. https://pubchem.ncbi.nlm.nih.gov/compound/167312357
  2. Ji, L., Jiang, H., An, P., et al. (2021). IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1b study. EClinicalMedicine, 39, 101088. https://pubmed.ncbi.nlm.nih.gov/34430840/
  3. Pocai, A. (2014). Action and therapeutic potential of oxyntomodulin. Molecular Metabolism, 3(3), 241-251. https://pubmed.ncbi.nlm.nih.gov/24749050/
  4. Shirley, M. (2025). Mazdutide: first approval. Drugs, 85(12), 1621-1627. https://pubmed.ncbi.nlm.nih.gov/41028652/
  5. Innovent Biologics. (2025, June 27). Innovent announces mazdutide, first dual GCG/GLP-1 receptor agonist, received approval from China's NMPA for chronic weight management. https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-first-dual-gcgglp-1-receptor-agonist-received-approval-from-chinas-nmpa-for-chronic-weight-management-302493152.html
  6. Innovent Biologics. (2025, September 19). Innovent announces mazdutide received approval from China's NMPA for glycemic control in adults with type 2 diabetes. https://www.prnewswire.com/news-releases/innovent-announces-mazdutide-received-approval-from-chinas-nmpa-for-glycemic-control-in-adults-with-type-2-diabetes-302561434.html
  7. Ji, L., Jiang, H., Bi, Y., et al. (2025). Once-weekly mazdutide in Chinese adults with obesity or overweight. New England Journal of Medicine, 392(22), 2215-2225. https://pubmed.ncbi.nlm.nih.gov/40421736/
  8. Gao, L., Jiang, H., Cai, H., et al. (2026). Treatment with 9-mg mazdutide for weight reduction in Chinese adults with obesity: the GLORY-2 randomized clinical trial. JAMA, 336(5), 377-388. https://pubmed.ncbi.nlm.nih.gov/42251595/
  9. Zhu, D., Zhao, J., Cai, H., et al. (2026). Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature, 652(8108), 174-180. https://pubmed.ncbi.nlm.nih.gov/41407859/
  10. Guo, L., Zhang, B., Xue, X., et al. (2026). Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature, 652(8108), 181-188. https://pubmed.ncbi.nlm.nih.gov/41407860/
  11. Hsia, S. H., Bays, H. E., Billings, L. K., et al. (2026). Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial. Lancet Diabetes & Endocrinology, 14(11), 879-893. https://pubmed.ncbi.nlm.nih.gov/42628555/
  12. Zhang, B., Cheng, Z., Chen, J., et al. (2024). Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Diabetes Care, 47(1), 160-168. https://pubmed.ncbi.nlm.nih.gov/37943529/
  13. U.S. Food and Drug Administration. (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  14. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf